The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Human Herpesvirus 8 (HHV-8) Infections and features dormant and discontinued products.
GlobalData tracks two drugs in development for Human Herpesvirus 8 (HHV-8) Infections by two companies/universities/institutes. The top development phase for Human Herpesvirus 8 (HHV-8) Infections is preclinical with one drugs in that stage. The Human Herpesvirus 8 (HHV-8) Infections pipeline has two drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Human Herpesvirus 8 (HHV-8) Infections pipeline products market are: Microbiotix and AlloVir.
The key targets in the Human Herpesvirus 8 (HHV-8) Infections pipeline products market include Serine/Threonine Protein Kinase UL97 (HSRF3 Protein or Ganciclovir Kinase or UL97 or EC 2.7.11.), and DNA Polymerase (EC 2.7.7.7).
The key mechanisms of action in the Human Herpesvirus 8 (HHV-8) Infections pipeline product include DNA Polymerase (EC 2.7.7.7) Inhibitor with one drug in Phase I. The Human Herpesvirus 8 (HHV-8) Infections pipeline products include one routes of administration with the top ROA being Oral and two key molecule types in the Human Herpesvirus 8 (HHV-8) Infections pipeline products market including Cell Therapy, and Small Molecule.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Human Herpesvirus 8 (HHV-8) Infections overview
Human herpesvirus-8 (HHV-8), also known as Kaposi’s sarcoma-associated herpesvirus (KSHV), is a gamma herpesvirus that infects various cell types, including endothelial cells, lymphocytes, and dendritic cells. HHV-8 is the etiological agent of Kaposi’s sarcoma (KS), a vascular tumor that often affects immunocompromised individuals, such as those with AIDS or organ transplant recipients. HHV-8 is also associated with rare lymphoproliferative disorders such as primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD). The transmission of HHV-8 is not fully understood, but sexual contact, blood transfusion, and saliva exchange are possible routes. The prevalence of HHV-8 infection varies widely across different geographic regions and populations, ranging from 1% to 80%. Most HHV-8 infections are asymptomatic and latent, but reactivation can occur under conditions of immune suppression or inflammation. There is currently no vaccine or specific treatment for HHV-8 infection or its related diseases.
For a complete picture of Human Herpesvirus 8 (HHV-8) Infections’s pipeline drug market, buy the report here.
Source link
#Human #Herpesvirus #HHV8 #Infections #drugs #development
